PROSTACYCLIN IMPROVES SURVIVAL AND REDUCES MICROCLOT FORMATION IN RABBIT ENDOTOXEMIA

1987 ◽  
Author(s):  
H Ditter ◽  
Fr R Matthias ◽  
R Voss ◽  
P Rottger
Keyword(s):  
Animal Species ◽  
Platelet Rich Plasma ◽  
Survival Rates ◽  
Blood Platelet ◽  
Treated Group ◽  
Control Group ◽  
Fibrin Deposition ◽  
Antiinflammatory Drugs ◽  
Acid Metabolites ◽  
Observation Period

Arachidonic acid metabolites seem to play a pivotal role in the pathophysiology of endotoxin (ET) shock. Therefore, attempts to intervene into the balance of eicosanoids may affect the course of ET shock. Several studies had shown a reduction of ET-induced mortality by non-steroidal antiinflammatory drugs in various animal species.We investigated whether an infusion of prostacyclin (PGI2) has an effect on survival rates and on the incidence of renal microclots in a rabbit shock model, which is based on an intravenous infusion of ET over 4 hours. Thirty animals being exposed to 75 μg/kg x h of lipopolysaccharide B, were allocated to three groups (E, El, EA; n=10 each), either receiving ET only (E), or PGI2 (500 ng/kg x min) simultaneously to ET (El), or aspirin (20 mg/kg) before ET (EA).A control group (C; saline infusion) consisted of 8 animals.At the end of the observation period (8 hours), the mortality of the treated animals (El and EA: 4/10 each) was significantly lower than in group E (8/10). However, only in the PGI2-treated group El a significant reduction of ET-induced glomerular fibrin deposition (GFD) was observed. Indices of GFD after semi-quantitative evaluation of renal slices were 10/27 (E), 1/24 (El), 3/21 (EA), and 0/24 (C). PGI2 exerted a platelet protective effect as shown by higher blood platelet counts (El 61.3 % vs. E 33.4 % of initial values), and a better preserved aggregation (El 60.5 % vs.E 31.7 %) and thromboxane formation capacity (El 52.0 ng/ml vs.E 23.4 ng/ml) of platelet rich plasma stimulated by 5 μg/ml collagen (all values at six hours after the start of ET infusion).ET caused a profound granulocytopenia which was not prevented by PGI2. Furthermore, PGI2 did not affect the ET-induced metabolic acidosis.These data confirm a beneficial effect of prostacyclin during a prolonged endotoxemia in rabbits, which may be a consequence of the known vasodilating, platelet inhibiting and cytoprotective properties of the substance.

scholarly journals Influence of an Implant Fixture Including a Freely Removable Micro-Locking Implant Prosthesis on Peri-Implant Tissues and Implant Prostheses: A Prospective Clinical Study

2021 ◽  
Vol 10 (15) ◽  
pp. 3321
Author(s):  
Young-Gun Shin ◽  
Won-Tak Cho ◽  
Ho-Kyung Lim ◽  
Su-Hyun Hwang ◽  
Ji-Hyeon Bae ◽  
...  
Keyword(s):  
Survival Rates ◽  
Treatment Method ◽  
Control Group ◽  
Prospective Clinical Study ◽  
Food Impaction ◽  
Radiographic Findings ◽  
The One ◽  
Implant System ◽  
Experimental Group ◽  
Observation Period

This prospective study was undertaken to evaluate the clinical usefulness of a newly developed one-piece, screw-free, and micro-locking implant system, which was designed to overcome the shortcomings of the existing implant systems. Thirty-eight patients were recruited and randomly and equally assigned to an experimental group (micro-locking one-piece fixture, MLF; n = 19) or a control group (micro-locking abutment, MLA). Cumulative implant survival rates, marginal bone resorptions, probing depths, plaque indices, bleeding indices, and complications were obtained by using clinical and radiographic findings at 6 months and 12 months after prosthesis placement. Complications that occurred multiple times for single implants were counted. During the 12 month observation period, survival rates were 100% in both groups. No significant intergroup differences were observed for marginal bone resorption, probe depth, or bleeding index. However, mean plaque index was significantly lower in the MLF group at 12 months (p < 0.05). During the 12-month observation period, food impaction (26.3%) was the maincomplication in the MLF group and screw loosening (5.3%), prosthesis detachment (5.3%), and food impaction (5.3%) were observed in the MLA group. The results of this study suggest that the one-piece micro-locking implant system offers a predictable treatment method.

Effectiveness of Platelet-Rich Plasma and Hyaluronic Acid for the Treatment and Care of Pressure Ulcers

2014 ◽  
Vol 17 (2) ◽  
pp. 152-158 ◽  
Author(s):  
Javier Ramos-Torrecillas ◽  
Olga García-Martínez ◽  
Elvira De Luna-Bertos ◽  
Francisco Manuel Ocaña-Peinado ◽  
Concepción Ruiz
Keyword(s):  
Wound Healing ◽  
Hyaluronic Acid ◽  
Peripheral Blood ◽  
Pressure Ulcers ◽  
Platelet Rich Plasma ◽  
Blood Platelet ◽  
Control Group ◽  
Treatment Groups ◽  
Ulcer Area ◽  
Complete Wound Healing

Platelet-rich growth factor (PRGF) is a natural source of growth factors (GF), while hyaluronic acid (HA) is a biopolymer present in the extracellular matrix of skin, cartilage, bone, and brain, among other tissues. Both are involved in the pathophysiological mechanisms underlying wound healing. The objective of this study was to evaluate the clinical efficacy (as measured by ulcer area) and safety (as measured by signs of infection) of PRGF and PRGF plus HA in the treatment of pressure ulcers (PUs). Patients ( N = 100) with 124 Stage II–III PUs were randomized to a control group ( n = 25 PUs) for standard care or to case groups for treatment with one ( n = 34 PUs) or two ( n = 25 PUs) doses of PRGF from their own peripheral blood, or two doses of PRGF plus HA ( n = 40 PUs). All ulcers were followed up every 3 days for a 36-day period. At 36 days, a significant reduction in ulcer area ( p ≤ .001) was observed in all treatment groups, with a mean reduction of more than 48.0% versus baseline. The greatest mean reduction (80.4% vs. baseline) was obtained with the PRGF plus HA regimen. Complete wound healing was observed in 32.0% of PUs treated with two doses of PRGF ( p ≤ .002) and in 37.5% of those treated with two doses of PRGF plus HA ( p ≤ .004). There were no signs of infection in any PUs during the 36-day follow-up period. The degree of wound healing was inversely correlated with the consumption of drugs such as statins and with the peripheral blood platelet levels of patients at baseline.

scholarly journals INFLUENCE OF GROWTH IN TREATED CLASS III GROWING PATIENTS WITH FACE MASK THERAPY AND UNTREATED PATIENTS

2019 ◽  
Vol 31 (4) ◽  
pp. 883-888
Author(s):  
Sofija Carceva Shalja ◽  
Sandra Atanasova
Keyword(s):  
Negative Impact ◽  
Face Mask ◽  
Treated Group ◽  
Control Group ◽  
Class Iii ◽  
Class Iii Malocclusion ◽  
Maxillary Protraction ◽  
Before And After ◽  
Maxillary Deficiency ◽  
Observation Period

Developing Class III Malocclusion in most of the cases affects dentofacial appearance. The goal of this study is to investigate the changes in the facial appearances in treated patients withFace mask orthopedic treatment and untreated Class III patients. The sample consisted 49 patients (boys and girls),with average age of 9 years, who had a Class III Malocclusion with an anterior crossbite and a component of maxillary deficiency. 28 of them were treated with protraction Face mask- Delair mask (petit tipe), and the other 21 were presenting the control group consisted of untreated Class III Patients.In treated group pretreatment and posttreatment cephalometric radiographs from 28 patients(15 males and 13 females) were analyzed and compared with the results of cephalometric analyzes in untreated group(observation period of 1 year). Results from these study showed forward displacement of maxilla(SNA p<0.05),increasing of maxillary length(Co-A p<0.05)correction of maxillary-mandibular relationship(ANB p<0.05) in treated group while in untreated groupvalues for the parameters in the upper jaw and inter jaw relationship before and after the observation period of 1 yearshowed no statistically significant changes pointing to the negative impact of incorrect skeletal terms in Class III growing patients.Based on our findings we can concluded that in Class III patients there is a big motivation for orthodontic treatment because their dentofacial appearance deviates from sociocultural norms.Therefore, an important objective of accepting maxillary protraction treatment in Class III malocclusion is providing nonsurgical alternative in the treatment and improving the physico-social wellbeing and appearance of the patients, especially during their teenage years.

Evaluation of the effect on the biological status of young sheep when using a symbiotic feed additive

2021 ◽  
Vol 1 (5) ◽  
pp. 57-62
Author(s):  
R. F. Ivannikova ◽  
◽  
N. V. Pimenov ◽  
Keyword(s):  
Animal Species ◽  
Live Weight ◽  
Feed Additives ◽  
Feed Additive ◽  
Control Group ◽  
Genus Bacillus ◽  
Negative Effect ◽  
Positive Effect ◽  
Spore Forming Bacteria ◽  
Observation Period

The article presents the results of studies on the use of synbiotic feed additives based on live spore-forming bacteria of the genus Bacillus, lysates of lactic acid bacteria and yeast to lambs of 10-day-old Volgograd breed in various doses. The use of the feed additive did not have a negative effect on the morphological parameters of the lambs ' blood. Physiological parameters for the entire observation period were within the reference values characteristic of this animal species. The positive effect of synbiotic feed additive was manifested by higher growth rates – an increase in the live weight of the lambs of the experimental groups compared to the control group.

scholarly journals In Vitro and In Vivo Activities of Newer Fluoroquinolones against Vibrio vulnificus

2002 ◽  
Vol 46 (11) ◽  
pp. 3580-3584 ◽  
Author(s):  
Hung-Jen Tang ◽  
Ming-Chung Chang ◽  
Wen-Chien Ko ◽  
Kun-Yen Huang ◽  
Chih-Lung Lee ◽  
...  
Keyword(s):  
Vibrio Vulnificus ◽  
Survival Rates ◽  
Treated Group ◽  
Inhibitory Effect ◽  
Clinical Strain ◽  
Control Group ◽  
Dilution Method ◽  
Agar Dilution Method

ABSTRACT The MICs of six fluoroquinolones as well as minocycline and cefotaxime for 46 clinical isolates of Vibrio vulnificus were determined by the agar dilution method. All the drugs tested had good activities against all isolates, with the MICs at which 90% of the isolates tested were inhibited (MIC90s) by five of the fluoroquinolones ranging between 0.03 and 0.06 μg/ml. The MIC90 of lomefloxacin, on the other hand, was 0.12 μg/ml. Time-kill studies were conducted with these agents and a clinical strain of V. vulnificus, VV5823. When approximately 5 × 105 CFU of V. vulnificus/ml was incubated with any one of the above-mentioned six fluoroquinolones at concentrations of two times the MIC, there was an inhibitory effect on V. vulnificus that persisted for more than 48 h with no noted regrowth. The efficacies of the fluoroquinolones were further evaluated in vivo in the mouse model of experimental V. vulnificus infection and compared to the efficacy of a combination therapy using cefotaxime plus minocycline. With an inoculum of 1.5 × 107 CFU, 28 (87.5%) of 32 mice in the cefotaxime-minocycline-treated group survived and 29 (91%) of the 32 mice in the moxifloxacin-treated group survived while none of the 32 mice in the control group did. With an inoculum of 3.5 × 107 CFU, the difference in survival rates among groups of 15 mice treated with levofloxacin (13 of 15), moxifloxacin (10 of 15), gatifloxacin (10 of 15), sparfloxacin (11 of 15), ciprofloxacin (12 of 15), or lomefloxacin (10 of 15) was not statistically significant while none of the 15 mice treated with saline survived. We concluded that the newer fluoroquinolones as single agents are as effective as the cefotaxime-minocycline combination in inhibiting V. vulnificus both in vitro and in vivo.

scholarly journals Novel Anion Liposome-Encapsulated Antisense Oligonucleotide Restores Susceptibility of Methicillin-Resistant Staphylococcus aureus and Rescues Mice from Lethal Sepsis by Targeting mecA

2009 ◽  
Vol 53 (7) ◽  
pp. 2871-2878 ◽  
Author(s):  
Jingru Meng ◽  
Hui Wang ◽  
Zheng Hou ◽  
Tao Chen ◽  
Jingguo Fu ◽  
...  
Keyword(s):  
Staphylococcus Aureus ◽  
Survival Rates ◽  
Treated Group ◽  
Antisense Oligodeoxynucleotide ◽  
Control Group ◽  
Dependent Manner ◽  
Concentration Dependent Manner ◽  
Lethal Sepsis ◽  
Mueller Hinton Agar ◽  
Novel Strategy

ABSTRACT β-Lactam resistance in methicillin (meticillin)-resistant Staphylococcus aureus (MRSA) is caused by the production of an additional low-affinity penicillin-binding protein 2a, which is encoded by the mecA gene. The disruption of mecA may inhibit mecA expression and thereafter lead to the restoration of MRSA susceptibility to β-lactams. In this study, we developed a novel anionic liposome for encapsulating and delivering the complexes of a specific anti-mecA phosphorothioate oligodeoxynucleotide (PS-ODN833) and polycation polyethylenimine (PEI). The efficiencies of liposome encapsulation of the complexes were around 79.7% ± 2.7%. The liposomes showed sustained release of PS-ODN833 at 37°C but very low levels of release at 4°C and room temperature. The addition of the encapsulated anti-mecA PS-ODN833-PEI complex to cultures of MRSA strains caused 45, 76, 82, and 93% reductions in mecA expression, accompanied by the inhibition of MRSA growth on Mueller-Hinton agar containing oxacillin (6 μg/ml) in a concentration-dependent manner. The encapsulated-PS-ODN833 treatment also reduced the MICs of five of the most commonly used antibiotics for MRSA clinical isolates to values within the sensitivity range and rescued mice from MRSA-caused septic death by downregulating mecA. The survival rates of septic mice increased from 0% for the control group to 53% for the PS-ODN833-treated group. The results were associated with reductions of bacterial titers in the blood of surviving mice. The findings of the present study indicate that an antisense oligodeoxynucleotide targeted to mecA can significantly restore the susceptibility of MRSA to existing β-lactam antibiotics, providing an apparently novel strategy for treating MRSA infections.

Renal response to vasopressin and indomethacin in cisplatin-treated rats

1987 ◽  
Vol 73 (4) ◽  
pp. 377-381 ◽  
Author(s):  
Christopher J. Lote ◽  
Ernest S. Harpur ◽  
Andrew Thewles ◽  
Donna J. Phipps
Keyword(s):  
Body Weight ◽  
Single Dose ◽  
Treated Group ◽  
Urine Flow ◽  
The Other ◽  
Control Group ◽  
Fischer 344 ◽  
Antidiuretic Effect ◽  
Natriuretic Effect ◽  
Observation Period

1. Cisplatin [6 mg/kg body weight, in 0.9% (w/v) NaCl] was injected intraperitoneally as a single dose to two groups of rats (Fischer 344 strain). Two further groups of rats, injected intraperitoneally with an equivalent volume of 0.9% (w/v) NaCl, were used as controls. The cisplatin-treated rats developed a pronounced polyuria which did not recover during an 18 week observation period. 2. After 21 weeks, one group of the cisplatin-treated animals received a 6 h infusion of 2.5% d-glucose. Vasopressin (60 μ-units min−1 100 g−1 body weight) was incorporated into the infusate for the final 2 h. A control group of animals received an identical infusion. One week later the other group of cisplatin-treated rats received a 6 h infusion of 0.9% (w/v) NaCl. Indomethacin was incorporated into the infusate for 15 min, at 3 h 52.5 min, to deliver a dose of 10 mg/kg body weight. A control group again received an identical infusion. 3. Cisplatin did not impair the antidiuretic effect of vasopressin, but it reduced the natriuretic effect of vasopressin, and also impaired the ability of the animals to produce concentrated urine. 4. Cisplatin did not alter basal PGE2 excretion, or the reduction in PGE2 excretion induced by indomethacin. However, the urine flow in the cisplatin-treated group did not fall after indomethacin, whereas there was a fall in urine flow in the control group.

scholarly journals Peritoneal Reactivity Evaluation in Horses Subjected to Experimental Small Colon Enterotomy and Treated with Subcutaneous Heparin

2014 ◽  
Vol 2014 ◽  
pp. 1-9 ◽  
Author(s):  
Juliana de Moura Alonso ◽  
Karoline Alves Rodrigues ◽  
Ana Lúcia Miluzzi Yamada ◽  
Marcos Jun Watanabe ◽  
Ana Liz Garcia Alves ◽  
...  
Keyword(s):  
Abdominal Surgery ◽  
Peritoneal Fluid ◽  
Abdominal Cavity ◽  
Treated Group ◽  
Heparin Therapy ◽  
Control Group ◽  
Fibrin Deposition ◽  
Abdominal Adhesions ◽  
Subcutaneous Heparin ◽  
D Dimer

Heparin is routinely administered in postoperative abdominal surgery aiming to prevent adhesions formation; however, there is no consensus indicating its effectiveness. This study evaluated the effect of heparin on peritoneal reactivity after abdominal surgery, through the association between peritoneal fluid features and ultrasonographic and laparoscopic examination. Ten adult horses were used: control group (CG) and treated group (TG). Both groups underwent laparotomy and small colon enterotomy. TG received subcutaneous heparin at 150 IU/kg every 12 hours for 5 days. The animals underwent ultrasonography and peritoneal fluid examination prior to enterotomy (M0) 12 hours (M1), 1 day (M2), 2 days (M3), 4 days (M4), 6 days (M5), 10 days (M6), and 14 days after enterotomy (M7) with laparoscopic examination being performed on the fifth postoperative day. Peritoneal inflammatory response was observed in both groups. The peritoneal fluid of TG animals showed higher echogenicity during heparin therapy. No inflammatory difference was observed between groups through peritoneal fluid features, except for the higher D-dimer concentration in CG. On laparoscopy, slightly diffuse peritoneal reactivity for both groups was observed, being higher for TG. Laparoscopy and ultrasonography association allowed detailed access to the abdominal cavity. Ultrasonography assessed the diffuse peritoneal inflammation, and laparoscopy allowed the detailed analysis of the segments. No gross beneficial reactions resulting from the use of heparin on peritoneal reactivity were observed; however, it was observed by D-dimer evaluation that the TG had less fibrin deposition, which is directly related to a lower rate of abdominal adhesions formation.

scholarly journals Effect of Intrauterine Infusion of Equine Fresh Platelets-Rich Plasma (PRP) or Lyophilized PRP (L-GFequina) on Ovarian Activity and Pregnancy Rate in Repeat Breeder Purebred Arabian Mares

Animals ◽  
2021 ◽  
Vol 11 (4) ◽  
pp. 1123
Author(s):  
Ahmed Dawod ◽  
Jordi Miro ◽  
Hamed T. Elbaz ◽  
Hossam Fahmy ◽  
Ahmed S. Abdoon
Keyword(s):  
Pregnancy Rate ◽  
Cycle Length ◽  
Endometrial Thickness ◽  
Platelet Rich Plasma ◽  
Treated Group ◽  
Control Group ◽  
Ovarian Activity ◽  
Estrus Cycle ◽  
Significant Difference ◽  
Estrus Phase

This study was designed to examine the effect of the intrauterine infusion of platelet-rich plasma (PRP) or equine lyophilized growth factor (L-GFequina) on the follicular growth, endometrial thickness, estrus cycle length, and pregnancy rate in purebred Arabian mares. A total of 73 purebred Arabian mares who experienced repeat breeding for three successive cycles were randomly divided into the following three groups: control group, without treatment; second Group (PRP group), in which mares were intrauterine infused with 20 mL of fresh PRP on the second day after the end of physic estrus phase; and the third group (L-GFequina Group), consisting of mares that were intrauterine infused with 20 mL of reconstituted lyophilized horse platelets growth factors (L-GFequina) on the second day after the estrus phase. The results showed no significant difference between control and treated groups in the diameter of the preovulatory follicles during the post treatment cycle. The endometrium thickness increased significantly in the L-GFequina and PRP groups ahead of the non-treated group. Intrauterine L-GFequina or PRP administration shortened the estrus cycle length. A higher pregnancy rate was recorded in the L-GFequina and PRP treated mares. In conclusion, the intrauterine infusion of L-GFequina or PRP increased the endometrial thickness and pregnancy rate and could be used to improve fertility in Arabian purebred mares who experienced from repeat breeding.

Adjuvant Immunotherapy of Patients With High-Risk Melanoma Using Vaccinia Viral Lysates of Melanoma: Results of a Randomized Trial

2002 ◽  
Vol 20 (20) ◽  
pp. 4181-4190 ◽  
Author(s):  
Peter Hersey ◽  
Alan S. Coates ◽  
William H. McCarthy ◽  
John F. Thompson ◽  
Robert W. Sillar ◽  
...  
Keyword(s):  
High Risk ◽  
Survival Rates ◽  
Treated Group ◽  
Multicenter Trial ◽  
Phase Iii ◽  
Control Group ◽  
High Risk Melanoma ◽  
Phase Ii Studies ◽  
Risk Melanoma ◽  
Cox Analysis

PURPOSE: Patients with high-risk melanoma treated by immunotherapy with vaccinia viral lysates were found in phase II studies to have improved survival compared with historical controls. We therefore elected to test this therapy in a phase III study. PATIENTS AND METHODS: A prospective, randomized, multicenter trial to determine whether immunotherapy with a vaccine prepared from vaccinia melanoma cell lysates (VMCL) over a 2-year period after definitive surgery would improve relapse-free survival (RFS) and overall survival (OS) in patients with American Joint Committee on Cancer stage IIB and III melanoma compared with a control group treated only with surgery. RESULTS: A total of 700 patients were randomized: 353 to VMCL and 347 to no immunotherapy. Seventy-seven percent had lymph node (LN) metastases and 66% had clinically detected LN metastases. Analysis on the basis of all eligible, randomized patients (n = 675) found, after a median follow-up period of 8 years, a median OS of 88 months in the control versus 151 months in the treated group (hazard ratio [HR], 0.81; 95% confidence interval [CI], 0.64 to 1.02; P = .068 by stratified univariate Cox analysis). At 5 and 10 years, survival rates for control and treated patients were 54.8% v 60.6% and 41% v 53.4%, respectively. Median RFS was 43 months in the control group compared with 83 months in the treated group (HR, 0.86; 95% CI, 0.7 to 1.07; P = .17). RFS at 5 years was 50.9% for the treated group and 46.8% for the control group. There were no selective benefits from the vaccine for particular subsets of patients. CONCLUSION: Immunotherapy with VMCL was not associated with a statistically significant improvement in OS or RFS, with CIs not ruling out important gains from such treatment.

Sign in / Sign up

Export Citation Format

Share Document